Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? (2018)

First Author: Blinman PL
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdx715

PubMed Identifier: 29177440

Publication URI: http://europepmc.org/abstract/MED/29177440

Type: Journal Article/Review

Volume: 29

Parent Publication: Annals of oncology : official journal of the European Society for Medical Oncology

Issue: 2

ISSN: 0923-7534